ITOC, PTHL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) Securities Lawsuit

A securities class action alleges iTonic Holdings director Pengfei Zhang helped oversee disclosures that failed to identify manipulation risks tied to fabricated Gilead Sciences acquisition rumors. iTonic shares collapsed roughly 95% in one session, from a $32.00 intraday high on July 28, 2025 to about $1.65 on July 29, after multiple Nasdaq volatility halts. The lawsuit asserts Exchange Act and Securities Act claims against the company, directors, IPO underwriters and auditor; investors have until September 29, 2026 to seek lead-plaintiff status.

Analysis

This is primarily a residual-liquidity and governance-risk event rather than a new fundamental catalyst. For ITOC, adding a director tied to the controlling shareholder increases the probability that any future capital raise, reverse split, related-party transaction, or delisting remediation is priced on punitive terms; the relevant valuation framework is optionality on a thinly traded microcap, not earnings power. The near-term lead-plaintiff deadline is unlikely to create incremental selling by itself, but renewed attention can widen spreads and further reduce market-maker willingness to warehouse inventory.

The more material 1-3 month risk is that discovery or insurance disclosures reveal a weak D&O coverage position, limited recoverable assets, or additional inconsistencies in historic disclosures. That would impair any perceived litigation recovery while raising going-concern and financing risk; conversely, a credible independent-board overhaul, audited operational update, and evidence of normalized trading would be required before the governance discount can compress. GILD has no investable read-through absent independently corroborated evidence of a commercial or corporate connection; rumor-driven association is a negligible fundamental risk to a large-cap issuer.

Contrarianly, the equity has already absorbed most of the initial collapse, so an outright short can carry unfavorable borrow, locate, halt, and squeeze risk relative to remaining downside. The cleaner expression is to avoid treating a very low nominal share price as value: concentrated control and impaired disclosure credibility can keep the equity structurally uninvestable for 6-18 months, even if litigation headlines periodically produce speculative rebounds.

Key Decisions for Investors

• Avoid new long exposure to ITOC pending verification of current cash, auditor status, NASDAQ compliance, D&O limits, and any financing terms; a low share price is not a catalyst. Reassess only after an independently credible filing addresses these items.
• For holders able to borrow shares, use any litigation-deadline or retail-driven rebound over the next 1-3 months to establish a small, tightly risk-controlled ITOC short rather than chasing weakness; cap gross exposure given halt/borrow risk and cover on a disclosed equity financing or independently validated governance reset.
• Do not position in GILD on this item. Maintain an alert for any SEC filing, GILD statement, or regulator action that establishes an actual connection; absent that, expected earnings and valuation impact is immaterial.
• Monitor ITOC for a going-concern qualification, reverse-split proposal, NASDAQ deficiency notice, or discounted convertible financing over the next two reporting cycles; any of these would validate a continued structural-risk thesis, while clean audited filings and board independence changes would falsify it.